Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA FRESENIUS KABI ONCO. AJANTA PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 27.6 22.1 124.7% View Chart
P/BV x 6.8 3.1 219.1% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 AJANTA PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
FRESENIUS KABI ONCO.
Mar-13
AJANTA PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,422176 807.9%   
Low Rs89879 1,143.4%   
Sales per share (Unadj.) Rs233.537.7 619.6%  
Earnings per share (Unadj.) Rs44.05.1 863.2%  
Cash flow per share (Unadj.) Rs52.26.7 775.7%  
Dividends per share (Unadj.) Rs9.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs255.142.5 599.6%  
Shares outstanding (eoy) m88.02158.23 55.6%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.03.4 147.1%   
Avg P/E ratio x26.425.0 105.6%  
P/CF ratio (eoy) x22.218.9 117.5%  
Price / Book Value ratio x4.53.0 152.0%  
Dividend payout %20.50-   
Avg Mkt Cap Rs m102,08120,135 507.0%   
No. of employees `0006.81.2 590.3%   
Total wages/salary Rs m4,307703 612.5%   
Avg. sales/employee Rs Th3,022.65,176.2 58.4%   
Avg. wages/employee Rs Th633.4610.4 103.8%   
Avg. net profit/employee Rs Th569.1699.6 81.3%   
INCOME DATA
Net Sales Rs m20,5545,963 344.7%  
Other income Rs m21118 1,171.1%   
Total revenues Rs m20,7655,981 347.2%   
Gross profit Rs m5,6641,430 396.1%  
Depreciation Rs m721258 279.5%   
Interest Rs m12-26 -44.6%   
Profit before tax Rs m5,1431,216 422.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,273342 372.0%   
Profit after tax Rs m3,870806 480.2%  
Gross profit margin %27.624.0 114.9%  
Effective tax rate %24.828.1 88.0%   
Net profit margin %18.813.5 139.3%  
BALANCE SHEET DATA
Current assets Rs m11,8125,102 231.5%   
Current liabilities Rs m3,7762,385 158.3%   
Net working cap to sales %39.145.6 85.8%  
Current ratio x3.12.1 146.3%  
Inventory Days Days77150 51.6%  
Debtors Days Days82113 72.0%  
Net fixed assets Rs m14,3985,148 279.7%   
Share capital Rs m175158 110.9%   
"Free" reserves Rs m22,2776,556 339.8%   
Net worth Rs m22,4526,732 333.5%   
Long term debt Rs m7952 0.7%   
Total assets Rs m26,96210,388 259.5%  
Interest coverage x444.3-45.8 -970.7%   
Debt to equity ratio x00.1 0.2%  
Sales to assets ratio x0.80.6 132.8%   
Return on assets %14.47.5 191.7%  
Return on equity %17.212.0 144.0%  
Return on capital %23.014.6 157.2%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m10,6825,298 201.6%   
Fx outflow Rs m2,1021,772 118.6%   
Net fx Rs m8,5803,525 243.4%   
CASH FLOW
From Operations Rs m3,7481,274 294.2%  
From Investments Rs m-2,228-1,204 185.0%  
From Financial Activity Rs m-1,475-196 752.0%  
Net Cashflow Rs m45-126 -35.8%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 1.6 0.3 516.7%  
FIIs % 7.6 9.6 79.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 9.1 186.8%  
Shareholders   20,968 42,599 49.2%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   NATCO PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  TORRENT PHARMA  PANACEA BIOTECH  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 470 Points Lower; Tata Motors & Tata Steel Fall 6%(Closing)

Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 18, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - NOVARTIS COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS